• Association of CSF Glucocerebrosidase Activity With the Risk of Incident Dementia in Patients With Parkinson Disease 

      Oftedal, Linn Silje Wathne; Maple-Grødem, Jodi; Dalen, Ingvild; Tysnes, Ole-Bjørn; Pedersen, Kenn Freddy; Alves, Guido Werner; Lange, Johannes (Peer reviewed; Journal article, 2022)
      Background and Objectives Variations in the glucocerebrosidase gene (GBA) are common risk factors for Parkinson disease (PD) and dementia in PD (PDD) and cause a reduction in the activity of the lysosomal enzyme ...
    • Association of SNCA Parkinson's Disease Risk Polymorphisms With Disease Progression in Newly Diagnosed Patients 

      Szwedo, Aleksandra A; Pedersen, Camilla C; Ushakova, Anastasia; Forsgren, Lars; Tysnes, Ole-Bjørn; Counsell, Carl E.; Alves, Guido Werner; Lange, Johannes; Macleod, Angus D.; Maple-Grødem, Jodi (Peer reviewed; Journal article, 2021-02)
      Objectives: To evaluate the impact of SNCA polymorphisms originally identified as risk factors for Parkinson's disease (PD) on the clinical presentation and progression of the disease in a large cohort of population-based ...
    • Cognitive Profile in Parkinson’s Disease Dementia Patients with Low versus Normal Cerebrospinal Fluid Amyloid Beta 

      Tufekcioglu, Zeynep; Lange, Johannes; Pedersen, Kenn Freddy; Tysnes, Ole-Bjørn; Alves, Guido Werner; Emre, Murat (Peer reviewed; Journal article, 2023)
      Introduction: In patients with Parkinson’s disease (PD), low cerebrospinal fluid (CSF) amyloid beta 1-42 (Ab42) at baseline is the most consistent CSF biomarker as a risk factor for developing dementia. Low CSF Ab42 is, ...
    • Combinatory microRNA serum signatures as classifiers of Parkinson's disease 

      Patil, Ketan S.; Basak, Indranil; Dalen, Ingvild; Hoedt, Esthelle; Lange, Johannes; Lunde, Kristin Aaser; Liu, Ying; Tysnes, Ole-Bjørn; Forsgren, Lars; Aarsland, Dag; Neubert, Thomas A.; Larsen, Jan Petter; Alves, Guido Werner; Møller, Simon Geir (Journal article; Peer reviewed, 2019-04)
      As current clinical diagnostic protocols for Parkinson's disease (PD) may be prone to inaccuracies there is a need to identify and validate molecular biomarkers, such as circulating microRNAs, which will complement current ...
    • Identification of diagnostic and prognostic biomarkers of PD using a multiplex proteomics approach 

      Maple-Grødem, Jodi; Ushakova, Anastasia; Pedersen, Kenn Freddy; Tysnes, Ole-Bjørn; Alves, Guido Werner; Lange, Johannes (Peer reviewed; Journal article, 2023-10)
      Given the complexity of Parkinson's disease (PD), achieving acceptable diagnostic and prognostic accuracy will require the support of a panel of diverse biomarkers. We used Proximity extension assays to measure a panel of ...
    • Identification of diagnostic and prognostic biomarkers of PD using a multiplex proteomics approach 

      Maple-Grødem, Jodi; Ushakova, Anastasia; Pedersen, Kenn Freddy; Tysnes, Ole-Bjørn; Alves, Guido Werner; Lange, Johannes (Peer reviewed; Journal article, 2023-09)
      Given the complexity of Parkinson's disease (PD), achieving acceptable diagnostic and prognostic accuracy will require the support of a panel of diverse biomarkers. We used Proximity extension assays to measure a panel of ...
    • Inflammatory biomarkers in newly diagnosed patients with Parkinson’s disease and related neurodegenerative disorders 

      Pedersen, Camilla Christina; Ushakova, Anastasia; Skogseth, Ragnhild Eide; Alves, Guido Werner; Tysnes, Ole-Bjørn; Aarsland, Dag; Lange, Johannes; Maple-Grødem, Jodi (Peer reviewed; Journal article, 2023)
      Background and Objectives Neuroinflammation contributes to Parkinson disease (PD) pathology, and inflammatory biomarkers may aid in PD diagnosis. Proximity extension assay (PEA) technology is a promising method for multiplex ...
    • Seed Amplification Assay as a Diagnostic Tool in Newly-Diagnosed Parkinson's Disease 

      Oftedal, Linn Silje Wathne; Maple-Gørdem, Jodi; Tysnes, Ole-Bjørn; Alves, Guido Werner; Lange, Johannes (Peer reviewed; Journal article, 2023)
      Seed amplification assays (SAA) are the first credible molecular assay for Parkinson’s disease (PD). However, the value of SAA to support the clinicians’ initial diagnosis of PD is not clear. In our study, we analyzed ...
    • A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson's disease 

      Pedersen, Camilla C; Lange, Johannes; Førland, Marthe Gurine; Macleod, Angus D.; Alves, Guido Werner; Maple-Grødem, Jodi (Peer reviewed; Journal article, 2021-07)
      There is great heterogeneity in both the clinical presentation and rate of disease progression among patients with Parkinson’s disease (PD). This can pose prognostic difficulties in a clinical setting, and a greater ...